Advil, Aleve top picks
Wyeth's Advil and Bayer's Aleve were identified as pain relievers of choice for back and neck pain by half of respondents in a Spine-health.com survey of OTC product preferences. Advil was the top choice in the month-long online poll, with 26 percent (236) of the 899 voters selecting the ibuprofen, according to poll results published April 23. Naproxen sodium Aleve was picked by 24 percent (216) of respondents. McNeil's Motrin ibuprofen was the choice of 13 percent (114) and the firm's Tylenol acetaminophen was picked by 11 percent (100) of participants, Spine-health.com says. Bristol-Myers Squibb's Excedrin was chosen by 6 percent (52) of respondents and aspirin 5 percent (41). Chicago-based Spine-health.com says the poll was its first seeking consumers' preferences for OTC pain relievers, although it frequently seeks reader input...
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
The US FDA says its release of complete response letters for products subsequently approved by the agency is just a first step toward releasing rejection letters when they are issued, assuming legal issues can be resolved.
The FDA's recent announcement of plans to expand unannounced inspections at ex-US facilities should put firms on advance notice that their next foreign facility inspection may not be preannounced, Ivy Sweeney, acting head of the agency's drug inspections office said.
New US FDA drugs center director George Tidmarsh’s data-centric comments at a Reagan-Udall Foundation meeting on unapproved fluoride products could suggest patients’ and caregivers’ experiences will carry less weight in benefit-risk decisions under his leadership.